Clinical trials: Psychotic Disorder
Schizophrenia, Mental Disorder
Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole
The purpose of this study is to determine the usability of the Medical Information Device #1 (MIND1) system in adults with schizophrenia who are treated with oral aripiprazole.
- Conditions
- Schizophrenia, Mental Disorder, Nervous System Diseases
- Trial name
- NCT02219009
- Testing
- MIND1 System
- Where
- 6 sites in United States
- Volunteers
- 67 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)
This study is to evaluate the safety and efficacy of the study drug compared to placebo in the treatment of cognitive impairment in men with schizophrenia.
- Trial name
- NCT00848484
- Testing
- MK5757
- Volunteers
- 54 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia
The purpose of this trial is to evaluate the dose distribution, effectiveness and safety in patients with schizophrenia who are switched from an oral atypical antipsychotic to Paliperidone ER.
- Trial name
- NCT00473434
- Testing
- Paliperidone
- Volunteers
- 64 people
- Sponsor
- Janssen-Cilag Pty Ltd
Schizophrenia, Schizophreniform Disorder
Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
This study will evaluate the long-term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder
- Conditions
- Schizophrenia, Schizophreniform Disorder, Bipolar I Disorder
- Trial name
- NCT03201757
- Testing
- ALKS 3831
- Where
- 85 sites in United States, Austria and 11 more
- Volunteers
- 523 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy
Evaluate the safety and tolerability of multiple subcutaneous injections of various dosages of risperidone with clinically stable schizophrenia
- Trial name
- NCT01677377
- Testing
- Risperidone, RBP-7000
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Indivior Inc.
Schizophrenia
A Study to Evaluate Participants Satisfaction, Quality of Life and Effectiveness of Flexible-Dose of Paliperidone Extended Release (ER) in Participants With Schizophrenia, Previously Treated With Risperidone
The purpose of this study is to evaluate effectiveness, tolerability (how well a participant can stand a particular medicine or treatment), and safety of flexible-dose of paliperidone extended release (ER) in participants with…
- Trial name
- NCT01010776
- Testing
- Paliperidone Extended Release (ER)
- Where
- 10 sites in Brazil
- Volunteers
- 223 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Schizophrenia
Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031
Open label extension study of Ziprasidone, evaluation of safety of long term use of ziprasidone
- Trial name
- NCT00174447
- Testing
- Ziprasidone
- Where
- 14 sites in France
- Volunteers
- 43 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Chronic Disease, Mental Disorder
Reducing Cardiovascular Risk in Adults With Serious Mental Illness
This purpose of this study is to adapt, implement and test the ability of a sophisticated point-of-care electronic health record-based clinical decision support that identifies and prioritizes all available evidence-based…
- Conditions
- Chronic Disease, Mental Disorder, Health Behavior, Bipolar Disorder
- Trial name
- SMIWizard (NCT02451670)
- Testing
- Prioritized Clinical Decision Support
- Where
- 3 sites in United States
- Volunteers
- 10,347 people
- Sponsor
- HealthPartners Institute
Schizophrenia
An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
This is a Phase 3b, 3-year, open-label, multi-center study in which patients with DSM-5 diagnosis of schizophrenia whose current medication(s) is not well tolerated and/or clinical symptoms are not well controlled will be…
- Trial name
- PENNANT (NCT05643170)
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Cancer, Severe Major Depression
Bridge: Proactive Psychiatry Consultation and Case Management for Patients With Cancer
The purpose of this research is to understand if it is helpful for patients with mental illness to be connected to a psychiatrist and case manager at the time of cancer diagnosis.
- Conditions
- Cancer, Severe Major Depression, Schizophrenia, Bipolar Disorder
- Trial name
- NCT03360695
- Testing
- Proactive Psychiatry Consultation (PPC), Enhanced Usual Care (EUC)
- Where
- United States
- Volunteers
- 185 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo.
- Trial name
- NCT04072354
- Testing
- SEP-363856 50mg, SEP-363856 75mg
- Where
- 53 sites in United States, Bulgaria and 4 more
- Volunteers
- 463 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients
The purpose of this study is to determine whether weight gain will be significantly less in LY2140023 than aripiprazole in patients with schizophrenia.
- Trial name
- NCT01328093
- Testing
- LY2140023, Aripiprazole
- Where
- 51 sites in United States, Austria and 8 more
- Volunteers
- 678 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients
Schizophrenia is a devastating and costly illness. One-third to one-half of people with schizophrenia do not respond to the most current drugs leaving clozapine as the best alternative for treatment.
- Trial name
- NCT01433055
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Maryland, Baltimore
Mania (Neurotic)
A Probiotic Intervention to Prevent Relapse Following Hospitalization for Mania
This will be a 24-week, randomized, double-blind, placebo-controlled trial of adjunctive probiotic therapy in 66 persons hospitalized with a manic or mixed episode.
- Trial name
- NCT03383874
- Testing
- Probio-Tec BG-VCap-6.5
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of Texas Southwestern Medical Center
Schizophrenia, Schizoaffective Disorder
Minocycline Augmentation to Clozapine
The proposed pilot study will compare minocycline augmentation with clozapine in individuals with high vs low inflammation as measured by CRP.
- Trial name
- NCT02124811
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Schizophrenia
A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.
- Trial name
- NCT01614899
- Testing
- SM-13496 40mg, SM-13496 80mg
- Where
- 4 sites in Japan, Malaysia and 2 more
- Volunteers
- 457 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Schizophrenia
CAE for Poorly Adherent Individuals With Schizophrenia
This project aims to evaluate the feasibility, acceptability and preliminary efficacy of remotely delivered CAE among patients with schizophrenia (CAE-S).
- Trial name
- CAE-S (NCT06061952)
- Testing
- Customized Adherence Enhancement for Schizophrenia (CAE-S), Enhanced Treatment as Usual (eTAU)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia
Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
This study is designed as a 3-part trial to evaluate the safety of a novel depot formulation of iloperidone, compare 2 depot dosage forms, and perform dose ranging of 1 chosen form in support of a monthly depot dosing regimen.
- Trial name
- NCT01348100
- Testing
- Iloperidone crystalline formulation, Iloperidone microparticle formulation, Oral iloperidone
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia
The primary objective of this study was to continue to provide aripiprazole intramuscular (IM) depot treatment (400 milligrams [mg] or 300 mg) to participants with schizophrenia completing the 52-week, open-label safety and…
- Trial name
- ASPIRE (NCT01129882)
- Testing
- Aripiprazole
- Where
- 157 sites in United States, Argentina and 22 more
- Volunteers
- 709 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizophrenia; Psychosis
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)
This is a Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multicenter inpatient study to examine the efficacy and safety of KarXT in adult subjects who are acutely psychotic with a Diagnostic and…
- Trial name
- NCT04738123
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 32 sites in United States, Ukraine
- Volunteers
- 256 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company